Multiple sclerosis and related disorders · 2024
Exploring humor as a coping factor against depressive mood and fear of progression in people with multiple sclerosis with moderate disability: A cross-sectional analysis of a rehabilitation cohort.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nielsen Jörn, Görtz Sarah, Aschermann Ellen, Saliger Jochen, Hennecken Eva, Eschweiler Mareike, Karbe Hans, Kalbe Elke, Folkerts Ann-Kristin
Аннотация
BACKGROUND: People with multiple sclerosis (pwMS) face disease-related stress throughout their lives, often resulting in depressive mood and fear of progression (FoP). People with a pronounced sense of humor demonstrate greater resilience to stress and tend to perceive threats as challenges. This research investigates whether humor can be identified as a relevant coping factor in pwMS regarding depressive mood and FoP.
METHODS: Participants were 77 German inpatients aged 25-64 years with predominantly relapsing-remitting MS. Blockwise regression analyses were conducted to examine the relationship between humor skills (Sense of Humor Scale, SHS), depressive mood (Centre for Epidemiologic Studies Depression Scale, CES-D), and fear of progression (Fear of Progression-Questionnaire, FoP-Q), adjusting for demographic, disease-specific, and self-management variables. Correlational and moderator analyses were conducted to evaluate the impact of humor styles (Comic Style Markers, CSM) and self-observation (as a self-distancing measure, Questionnaire to Assess Resources and Self-Management Skills) on these relationships.
RESULTS: The summed SHS score was found to be a significant unique determinant for less depressive mood (CES-D, RΔ = 0.05, p = .005), low FoP (FoP-Q sum score, RΔ = 0.06, p = .004), and greater anxiety coping (FoP-Q anxiety coping, RΔ = 0.06, p = .007). Only light humor style was associated with specific FoP-Q scales; the variable dark humor style was not correlated with any study variable. The subscale self-observation failed to moderate between SHS and emotional disorders.
CONCLUSION: Data indicate that humor skills in pwMS are associated with less depression and FoP, which argues for incorporating adaptive humor as a coping resource into psychosocial interventions for pwMS. However, further validation is needed through larger and longitudinal trials.
METHODS: Participants were 77 German inpatients aged 25-64 years with predominantly relapsing-remitting MS. Blockwise regression analyses were conducted to examine the relationship between humor skills (Sense of Humor Scale, SHS), depressive mood (Centre for Epidemiologic Studies Depression Scale, CES-D), and fear of progression (Fear of Progression-Questionnaire, FoP-Q), adjusting for demographic, disease-specific, and self-management variables. Correlational and moderator analyses were conducted to evaluate the impact of humor styles (Comic Style Markers, CSM) and self-observation (as a self-distancing measure, Questionnaire to Assess Resources and Self-Management Skills) on these relationships.
RESULTS: The summed SHS score was found to be a significant unique determinant for less depressive mood (CES-D, RΔ = 0.05, p = .005), low FoP (FoP-Q sum score, RΔ = 0.06, p = .004), and greater anxiety coping (FoP-Q anxiety coping, RΔ = 0.06, p = .007). Only light humor style was associated with specific FoP-Q scales; the variable dark humor style was not correlated with any study variable. The subscale self-observation failed to moderate between SHS and emotional disorders.
CONCLUSION: Data indicate that humor skills in pwMS are associated with less depression and FoP, which argues for incorporating adaptive humor as a coping resource into psychosocial interventions for pwMS. However, further validation is needed through larger and longitudinal trials.